The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Metabolic syndrome: prevalence and risk factors in Korean gout patients

  • Jung, Jae Hyun (Division of Rheumatology, Department of Internal Medicine, Korea University Guro Hospital) ;
  • Song, Gwan Gyu (Division of Rheumatology, Department of Internal Medicine, Korea University Guro Hospital) ;
  • Ji, Jong Dae (Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital) ;
  • Lee, Young Ho (Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital) ;
  • Kim, Jae-Hoon (Division of Rheumatology, Department of Internal Medicine, Korea University Guro Hospital) ;
  • Seo, Young Ho (Division of Rheumatology, Department of Internal Medicine, Korea University Ansan Hospital) ;
  • Choi, Sung Jae (Division of Rheumatology, Department of Internal Medicine, Korea University Ansan Hospital)
  • Received : 2016.02.26
  • Accepted : 2016.05.23
  • Published : 2018.07.01
⟨ Previous Next ⟩

Abstract

Background/Aims: We performed this study to investigate associations between metabolic syndrome, chronic kidney disease (CKD), and gout. Methods: We reviewed the medical records of 151 patients with gout at the Department of Rheumatology in Korea University Ansan Hospital. The following measures were examined: waist circumference, blood pressure, alcohol consumption, and levels of triglyceride, high density lipoprotein cholesterol, fasting serum glucose, serum uric acid (SUA), creatinine, insulin, and C-peptide. We assessed metabolic syndrome by the homeostasis model assessment of insulin resistance (HOMA-IR) index and renal function by the Modification of Diet in Renal Disease equation; patients were classified according to World Health Organization Asia-Pacific obesity criteria. Results: The prevalence of metabolic syndrome in gout patients (50.8%) was higher than in non-gout patients. The mean SUA level was significantly higher in gout patients with metabolic syndrome ($9.13{\pm}3.15mg/dL$) than in gout patients without metabolic syndrome ($8.14{\pm}2.07mg/dL$). The mean SUA level was also significantly higher in patients with gout and CKD ($9.55{\pm}2.86mg/dL$) than in patients with gout but no CKD ($7.74{\pm}2.27mg/dL$). In gout patients, HOMA-IR was positively correlated with waist circumference (r = 0.409, p = 0.001). Conclusions: The prevalence of metabolic syndrome in patients with gout was 50.8%, which is higher than the prevalence in the general Korean population. Hyperuricemia in gout patients was correlated with metabolic syndrome and CKD. Insulin resistance may provide clues to better understand the relationship between metabolic syndrome, CKD, and gout.

Keywords

Acknowledgement

Supported by : Korea University Medical College

References

  1. Ichikawa N, Taniguchi A, Urano W, Nakajima A, Yamanaka H. Comorbidities in patients with gout. Nucleosides Nucleotides Nucleic Acids 2011;30:1045-1050. https://doi.org/10.1080/15257770.2011.596499
  2. Dao HH, Harun-Or-Rashid M, Sakamoto J. Body composition and metabolic syndrome in patients with primary gout in Vietnam. Rheumatology (Oxford) 2010;49:2400-2407. https://doi.org/10.1093/rheumatology/keq274
  3. Rho YH, Choi SJ, Lee YH, et al. Prevalence of the metabolic syndrome in patients with gout. J Korean Rheum Assoc 2004;11:349-357.
  4. Rho YH, Choi SJ, Lee YH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci 2005;20:1029-1033. https://doi.org/10.3346/jkms.2005.20.6.1029
  5. Yoo HG, Lee SI, Chae HJ, Park SJ, Lee YC, Yoo WH. Prevalence of insulin resistance and metabolic syndrome in patients with gouty arthritis. Rheumatol Int 2011;31:485-491. https://doi.org/10.1007/s00296-009-1304-x
  6. Park S, Kim SJ, Lee M, Kang KA, Hendrix E. Prevalence and associated factors of metabolic syndrome among South Korean adults. J Community Health Nurs 2015;32:24-38. https://doi.org/10.1080/07370016.2015.992266
  7. Park MY, Kim SH, Cho YJ, Chung RH, Lee KT. Association of leisure time physical activity and metabolic syndrome over 40 years. Korean J Fam Med 2014;35:65-73.
  8. Lee CH, Sung NY. The prevalence and features of Korean gout patients using the national health insurance corporation database. J Rheum Dis 2011;18:94-100. https://doi.org/10.4078/jrd.2011.18.2.94
  9. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol 2002;29:1350-1355.
  10. Lee CH, Sung NY, Lee J, Bae SC. Factors associated with gout in South Koreans: analysis using the National Health Insurance Corporation and the National Health Screening Exam databases. Clin Rheumatol 2013;32:829-837. https://doi.org/10.1007/s10067-013-2183-9
  11. Jing J, Kielstein JT, Schultheiss UT, et al. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study. Nephrol Dial Transplant 2015;30:613-621. https://doi.org/10.1093/ndt/gfu352
  12. Prasad GV. Metabolic syndrome and chronic kidney disease: current status and future directions. World J Nephrol 2014;3:210-219. https://doi.org/10.5527/wjn.v3.i4.210
  13. Li Y, Chen Y, Liu X, et al. Metabolic syndrome and chronic kidney disease in a Southern Chinese population. Nephrology (Carlton) 2014;19:325-331. https://doi.org/10.1111/nep.12219
  14. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900. https://doi.org/10.1002/art.1780200320
  15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419. https://doi.org/10.1007/BF00280883
  16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470. https://doi.org/10.7326/0003-4819-130-6-199903160-00002
  17. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Executive Summary. Crit Pathw Cardiol 2005;4:198-203. https://doi.org/10.1097/00132577-200512000-00018
  18. International Obesity Task Force, World Health Organization Western Pacific Region. The Asia-Pacific perspective: redefining obesity and its treatment 2000. Manila (PH): World Health Organization Western Pacific Region, c2016 [cited 2016 Sep 27]. Available from: http://www.wpro.who.int/nutrition/documents/docs/Redefiningobesity.pdf.
  19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497. https://doi.org/10.1001/jama.285.19.2486
  20. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008;19:1204-1211. https://doi.org/10.1681/ASN.2007101075
  21. Zhu Y, Zhang Y, Choi HK. The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial. Rheumatology (Oxford) 2010;49:2391239-9. https://doi.org/10.1093/rheumatology/keq256
  22. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005;165:742-748. https://doi.org/10.1001/archinte.165.7.742
  23. Okita K, Iwahashi H, Kozawa J, et al. Homeostasis model assessment of insulin resistance for evaluating insulin sensitivity in patients with type 2 diabetes on insulin therapy. Endocr J 2013;60:283-290. https://doi.org/10.1507/endocrj.EJ12-0320
  24. Kim MK, Lee WY, Kang JH, et al. 2014 Clinical practice guidelines for overweight and obesity in Korea. Endocrinol Metab (Seoul) 2014;29:405-409. https://doi.org/10.3803/EnM.2014.29.4.405
  25. Yim HE, Yoo KH. Early life obesity and chronic kidney disease in later life. Pediatr Nephrol 2015;30:1255-1263. https://doi.org/10.1007/s00467-014-2922-4
  26. Nakagawa T, Mazzali M, Kang DH, et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003;23:2-7. https://doi.org/10.1159/000066303
  27. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5:1388-1393. https://doi.org/10.2215/CJN.01580210

Cited by

  1. New Classification Criteria and Guideline for Management of Gout vol.93, pp.4, 2018, https://doi.org/10.3904/kjm.2018.93.4.344
  2. Clinical characteristics of patients under 40 years old with early-onset hyperuricaemia: a retrospective monocentric study in China vol.9, pp.8, 2018, https://doi.org/10.1136/bmjopen-2018-025528
  3. Type 2 Diabetes Mellitus, Insulin Resistance, and Vitamin D vol.19, pp.10, 2018, https://doi.org/10.1007/s11892-019-1201-y
  4. What is the Best Choice for Urate-lowering Therapy for Korean? vol.27, pp.2, 2020, https://doi.org/10.4078/jrd.2020.27.2.78
  5. Effects of Urate-Lowering Therapy on Risk of Hyperlipidemia in Gout by a Population-Based Cohort Study and on In Vitro Hepatic Lipogenesis-Related Gene Expression vol.2020, pp.None, 2018, https://doi.org/10.1155/2020/8890300
  6. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors vol.16, pp.7, 2018, https://doi.org/10.1038/s41584-020-0441-1
  7. A global overview of genetically interpretable multimorbidities among common diseases in the UK Biobank vol.13, pp.1, 2018, https://doi.org/10.1186/s13073-021-00927-6